Business Context and Reporting Period
Company: Viking Therapeutics, Inc. (VKTX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Viking is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. The company has no commercial revenue and relies on equity financing to fund operations. Its primary assets are its drug candidates, most notably VK2735 (GLP-1/GIP dual agonist for obesity), VK2809 (TRβ agonist for NASH/MASH), and VK0214 (TRβ agonist for X-ALD).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Research & Development Expenses | $344,955 | $101,644 |
| General & Administrative Expenses | $48,387 | $49,277 |
| Total Operating Expenses | $393,342 | $150,921 |
| Net Loss | $(359,639) | $(109,963) |
| Net Loss Per Share (Basic & Diluted) | $(3.19) | $(1.01) |
| Cash, Cash Equivalents & Short-Term Investments | $705,739 | $902,612 |
| Accumulated Deficit | $(847,546) | $(487,907) |
| Net Cash Used in Operating Activities | $(278,685) | $(87,790) |
Note: The company has no debt obligations listed on the balance sheet as of December 31, 2025.
Material Changes vs. Prior Period
- Significant Increase in R&D Spend: Research and development expenses surged by 239.4% (from $101.6 million to $345.0 million). This increase was driven primarily by $202.7 million in additional clinical study costs and $32.5 million in manufacturing costs, reflecting the advancement of VK2735 into Phase 3 trials and the initiation of Phase 2 oral trials.
- Net Loss Expansion: Net loss increased from $110.0 million in 2024 to $359.6 million in 2025, consistent with the accelerated burn rate for clinical development.
- Investment Portfolio Shift: While total cash and investments decreased from $902.6 million to $705.7 million, the company generated $341.4 million in net cash from investing activities in 2025 due to the maturity of investments ($759.4 million) exceeding new purchases ($418.0 million).
- Financing Activity: In 2025, the company raised $73.9 million net from its At-The-Market (ATM) offering. This contrasts with 2024, which saw a major $597.1 million net raise from an underwritten public offering.
Guidance, Outlook, and Management Commentary
Clinical Pipeline Progress
- VK2735 (Obesity):
- Subcutaneous: Initiated two Phase 3 studies (VANQUISH-1 and VANQUISH-2) in June 2025. Enrollment for VANQUISH-1 was completed in November 2025. Phase 2 data showed up to 14.7% weight loss.
- Oral: Announced positive Phase 2 results in August 2025, achieving primary endpoints with up to 12.2% weight loss. Phase 3 oral studies are expected to initiate in Q3 2026.
- Maintenance: Initiated an exploratory Phase 1 maintenance dosing study in October 2025; enrollment completed in January 2026.
- VK2809 (NASH/MASH): Positive 52-week histologic data announced in June 2024 showed up to 75% of patients achieved NASH/MASH resolution. The company continues to evaluate this asset.
- VK0214 (X-ALD): Phase 1b results announced in October 2024 showed safety and significant reductions in VLCFA levels. The company intends to pursue partnering or licensing opportunities.
- DACRA Program: A new internal program for obesity; an IND application is planned for Q1 2026.
Liquidity and Capital Resources
As of December 31, 2025, the company held $705.7 million in cash, cash equivalents, and short-term investments. Management believes this is sufficient to fund operations through at least the first quarter of 2027. The company has an active ATM program with $75.7 million remaining capacity and a $250.0 million stock repurchase program authorized in February 2025 (no shares repurchased in 2025).
Risks and Contingencies
- Regulatory and Clinical Risk: As a clinical-stage company, Viking has no approved products. Success depends on the outcome of ongoing Phase 3 trials for VK2735. Failure in these trials would materially harm the business.
- Intellectual Property: The company relies heavily on a Master License Agreement with Ligand Pharmaceuticals for key assets (VK2809, VK0214, VK5211). Termination of this agreement would be catastrophic.
- Manufacturing: Entered into multi-year agreements with CordenPharma in March 2025 to secure capacity for VK2735. Prepayments are required from 2026 to 2028.
- Legal Proceedings: Ongoing litigation against Ascletis Defendants regarding trade secret misappropriation. The ITC ruled in Viking's favor in May 2025, but appeals were filed by both parties in September 2025.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $705.7 million cash balance against the projected burn rate, given the significant increase in R&D spend to $345 million in 2025.
- Phase 3 Enrollment: Confirm the timeline and enrollment status of the VANQUISH-2 Phase 3 trial, as only VANQUISH-1 enrollment was completed as of November 2025.
- Manufacturing Prepayments: Monitor the cash outflow impact of the CordenPharma prepayments scheduled to begin in 2026.
- Partnership Strategy: Assess progress on potential licensing or partnership deals for VK0214 and VK5211, as the company intends to out-license these assets rather than develop them fully internally.
- Legal Outcome: Track the status of the appeals in the Ascletis trade secret litigation, as the outcome could impact IP protection and potential damages.